rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Feasibility and Acceptability of a Stigma Text Message Intervention for People Who Use Drugs
Status: Recruiting

Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages are designed to address four components of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use.

This study is a single-group pilot trial to determine whether the intervention is feasible and acceptable to participants. All participants will receive the intervention. The primary outcomes are changes in stigma resistance and self-stigma from baseline to 4-week follow-up using self-report. Implementation and process outcomes will be measured to inform future intervention refinement.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Ages 18 and older at enrollment Residing in Scioto County, Ohio at time of enrollment Able to speak and read English Reliable daily access to smart phone with a data plan capable of sending and receiving text messages during the intervention period (4 weeks) Self-reported past 30-day use of illicit opioids (e.g., heroin, fentanyl), prescription opioids not as prescribed (e.g., oxycodone, buprenorphine), methamphetamine, or cocaine Willing to provide informed consent  Exclusion Criteria:  Unable to be consented due to cognitive impairment Planning to move out of the study area during the study period Unwilling or unable to comply with protocol requirements Currently incarcerated in a correctional facility - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Early Versus Conventional Loading for Fully Guided Immediate Implant Placement
Status: Not yet recruiting

Conventional loading protocol following implant placement 3 -6 months is considered the gold standard. However, early loading following 2 months after implant placement decreases the time and had a good survival rate.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients age range from 20-60 years. Molar tooth to be extracted due to periodontal diseases, peri- apical diseases, Endo-perio diseases, or tooth fracture. Primary implant stability is above 30 Ncm.  Exclusion Criteria:  History or presence of severe uncontrolled systemic disease. Heavy smokers (>10 cigarettes per day) or alcohol/drug abusers. Poor oral hygiene. Acute periapical infection. - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - MaximumAge: 45 Years - StdAgeList: Adult
The Importance of Inflammatory Markers Calculated From Preoperative and Postoperative Peripheral Blood Results in the Diagnosis and Treatment of Patients Operated for Hydatid Cyst of the Lung (Lung Echinococcus Granulosus)
Status: Recruiting

This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index values in the peripheral blood of patients diagnosed with pulmonary hydatid cyst (PHC) in the preoperative period and post-operative 3rd month. Although we have extensive data on hydatid liver cysts, there is limited information in the literature on the laboratory values of patients with PHC. This study aims to provide more scientific basis for the diagnosis and management of PHC and is considered as an inexpensive, reproducible and easily calculable method to improve the accurate diagnosis and management of AKH in clinical practice.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Between January 1, 2022 - December 1, 2023, patients with hydatid cyst of the lung who were hospitalized in the Thoracic Surgery Service  Exclusion Criteria:  Between January 1, 2022 and December 1, 2023, other patients admitted to the Thoracic Surgery Service - Gender: All - MinimumAge: 18 Years - MaximumAge: 83 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Peripheral blood results of patients hospitalized in the thoracic surgery clinic of S.B.Ü Van Training and Research Hospital due to hydatid cyst of the lung (surgery) will be evaluated. - SamplingMethod: Non-Probability Sample
Palmaris Longus Muscle and Dupuytren
Status: Recruiting

Dupuytren disease is a medical condition characterized by the painless formation of nodules in the palm of the hand. Cords are formed on the palmar fascia, a connective tissue sheet in the palm of the hand. This fascia is seen as the vestigial remnant of the palmaris longus tendon. The PLM attaches to the fascia palmaris. A muscle that not everyone has and can therefore be clearly missed. This raises the question of whether the presence of the musculus palmaris longus has any association with the development, recurrence and/or progression of DD and contractures. To investigate a potential predisposition, this study intend to assess the prevalence of the PLM in a group of individuals affected by DD and compare it with a control group (age matched, no signs of DD) without the condition.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The participant or his/her legally authorized representative voluntary signed the informed consent prior to the first assessment. 50 years of age or higher. Has Dupuytren disease (primary or recurrent). (Only applicable for participants of DD group) Has no medical conditions affecting the function of the hand (musculoskeletal pathology, vascular or neurological conditions such as CRPS, rheumatoid arthritis and paralysis). (Only applicable for participants of control group)  Exclusion Criteria:  Patients < 50 years Patients with cognitive impairments. Patients showing signs of medical conditions affecting the function of the hand (musculoskeletal pathology, vascular or neurological conditions such as CRPS, rheumatoid arthritis and paralysis). (Only applicable for participants of control group) - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 50 Years - StdAgeList: Adult, Older Adult
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Not yet recruiting

A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult patients (age> 18 years) treated with myeloablative or non-myeloablative HSCT 6 month prior and in outpatient follow-up without recurrent disease are eligible for inclusion.  Exclusion Criteria:  Patients with recurrence or subsequent malignancy requiring cancer treatment or lack of access to email and the Internet will be excluded. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
PRP Versus PRF Versus Conventional Treatment in Chronic Non-healing Skin Ulcers
Status: Recruiting

To compare the therapeutic efficacy of PRP and PRF: two relatively newer modalities in the management of chronic non-healing ulcers versus conventional treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients presenting with cutaneous ulcers greater than six weeks of duration and a size ranging between 0.5 and 10 cm, having a normal platelet count and hemoglobin >10 gm%.  Exclusion Criteria:  Patients with known bleeding disorders, and/or on oral anticoagulant therapy, uncontrolled diabetes, proven malignancy. Patients who are pregnant or lactating. Patients with actively infected ulcers, clinically defined by purulent discharge, green discoloration or fever, or positive culture, ulcers with exposed bone with no underlying granulation tissue, HIV, HCV, HBV patients. Patients who are with unrealistic expectations and unwilling to give consent for treatment or photography. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
A Comparative Effect of Echogenic Needle for Nerve Block on Acute and Chronic Postoperative Pain
Status: Recruiting

Surgical pain is a common complication after surgery, affecting patient recovery and treatment quality. >20% of patients suffer from chronic postoperative pain. China has >70 million surgeries yearly. Nerve block manages postoperative pain, with developing nerve block needles now used in clinics. Developed needles may have better pain management effects than non-developed ones, but their effect on reducing chronic pain remains unclear. This study aims to explore the effect of developed nerve block needles on postoperative pain and compare them to non-developed needles, providing new ideas and methods for pain management.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The age is above 18 years old and below 70 years old. patients whose surgical sites were in the chest, abdomen, upper limbs or lower limbs, including lobectomy, cholecystectomy, gastrointestinal resection, hysterectomy and other elective operations. This operation was the first operation during the hospitalization. Consent to participate in this study and sign an informed consent form.  Exclusion Criteria:  Patients with a history of alcohol or drug addiction. Patients with disturbance of consciousness before operation. Other conditions considered by the attending physician or researcher to be inappropriate for the study; History of chronic pain. Abnormal coagulation function. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Postoperative Intraperitoneal Pain Management Following Laparoscopic Cholecystectomy
Status: Recruiting

Postoperative pain management is essential and the inability to treat acute pain appropriately in the first 48 postoperative hours represents a risk factor for developing chronic pain. No. study has investigated IP granisetron as an adjuvant to standard care for postoperative pain management in patients undergoing LC.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients who are scheduled to undergo elective LC. Adults (males and/or females) between the ages of 18-70 years old.  Exclusion Criteria:  Chronic pain other than cholelithiasis. Patients who received analgesics or sedatives 24 h before scheduled surgery. Severe hepatic (Child Pugh Class B and C) and renal dysfunction (CrCl <30ml/min) Previous allergic response to vortioxetine, and granisetron. Pregnancy and lactation Patients with communication problems, cognitive dysfunction, or psychological disorders Daily corticosteroid use - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Status: Not yet recruiting

TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1). Group A receives 6 cycles of Toripalimab combined with CAPOX (ToriCAPOX). Group B receives SCRT (25Gy/5Fx) followed by 6 cycles of ToriCAPOX. TME surgery is scheduled after TNT while a watch and wait (W&W) option can be applied to patients achieving clinical complete response (cCR). The primary endpoint is complete response (CR, pathological complete response [pCR] plus cCR) rate. The secondary endpoints include the grade 3-4 acute adverse effects (AE) rate, anal preservation rate, 3-year DFS rate, etc.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Pathological confirmed adenocarcinoma; Clinical stage T3-4 and/or N+; The distance from anal verge ≤ 12 cm; Without distance metastases; Age 18-70 years old, female and male; KPS ≥ 70; Baseline blood and biochemical indicators meet the following criteria: neutrophils ≥ 1.5 × 10^9/L, Hb ≥ 90 g/L, PLT ≥ 100 × 10^9/L, ALT/ AST ≤ 2.5 ULN, Cr ≤ 1 ULN; With good compliance and signed the consent form.  Exclusion Criteria:  Pregnancy or breast-feeding women; Known history of other malignancies within 5 years; Known history of previous anti-tumor treatment, including radiotherapy, chemotherapy, immune checkpoint inhibitors, T cell-related therapy, etc; Known history of severe neurological or mental illness (such as schizophrenia, dementia or epilepsy); Current severe cardiac disease (cardiac dysfunction and arrhythmia), renal dysfunction and liver dysfunction; Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment; Uncontrolled infection which needs systemic therapy; Active autoimmune disease or immunodeficiencies, known history of organ transplantation or systematic use of immunosuppressive agents; Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1 to 2 antibody positive), active syphilis infection, active pulmonary tuberculosis infection Allergic to any component of the therapy. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study)
Status: Recruiting

Randomized clinical study analyzing the efficacy of colonoscopy assisted by the Computer Aided Detection (CADe) system compared to virtual chromoendoscopy with Narrow Band Imaging (NBI) in the detection of colon dysplasia in patients with long-standing inflammatory bowel disease (IBD).

Eligibility:
- EligibilityCriteria: INCLUSION CRITERIA:  Adults (age ≥18 years). Patients with IBD meeting the following criteria: Diagnosis of IBD confirmed by clinical and histological evidence. Disease extent (Montreal classification): 1) For Ulcerative Colitis (UC), Extensive colitis (E3): involvement proximal to the splenic flexure; or, Left-sided colitis (E2): involvement distal to the splenic flexure. 2) For Crohn's Disease (CD): Colon-only involvement (L2); or, Ileocolonic involvement (L3). Disease duration > 7 years. Patients with concommitant Primary Sclerosing Cholangitis, regardless of the extent of colonic involvement and disease duration. Written consent from the patient to undergo colonoscopy (signed informed consent).  EXCLUSION CRITERIA:  Personal history of colorectal cancer (CRC). Previous colectomy (partial or complete). Coagulopathy preventing biopsy or polypectomy/mucosal resection. Colonoscopy performed in the last 6 months. Pregnant or lactating women. Ulcerative colitis with involvement limited to the rectum or Proctitis (Montreal E1). Inadequate colonic preparation due to uncleavable fecal residue during colonoscopy: Boston Bowel Preparation Scale (BBPS) = 0 or 1 in any colon segment. Presence of inflammatory activity due to IBD on endoscopy:1) For UC: Endoscopic Mayo Score ≥ 2. 2) For CD: Simplified Endoscopic Activity Score (SES-CD) > 5. Incomplete lower digestive endoscopy (failure to reach the cecum). - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Diamine Oxidase and Adverse Pregnancy Outcomes
Status: Recruiting

In normal pregnancies, blood histamine concentration remains within normal values; however, the serum histaminolytic activity is increased. Histamine is mainly produced by mast cells, platelets, basophils, neurons and enterochromatin cells, where it is stored and released when required. Reduced DAO activities have been found in high-risk pregnancies. Lower DAO activity has been associated to miscarriage, fetal demise, preeclampsia, low birthweight and preterm birth. The placenta is very rich in DAO activity and is the principal source of increased histaminolytic activity in normal pregnancies.

First-trimester screening for preeclampsia (PE) is a routine screening which is performed in the first trimester. Women with a positive result are at a greater risk of PE but also other pregnancy complications such as stillbirth, preterm birth and low birthweight. These cases are prescribed aspirin until term. This intervention has demonstrated to significantly reduce the risk of PE and other complications. Unfortunately, aspirin does not avoid all cases with adverse outcomes, indicating that additional mechanisms may be involved in the development of such pregnancy complications, such as DAO decreased activity.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Single pregnancy Maternal age ≥18 High risk (≥1/50) in the first-trimester screening for preeclampsia Gestational age between 11+0 and 16+6 weeks of gestation  Exclusion Criteria:  Fetal malformation Fetal death Maternal digestive inflammatory disease or intolerance Refusal to give informed consent - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Single pregnancies between 11+0 and 16+6 weeks of gestation and high risk for preeclampsia in the first trimester screening (risk ≥1/50) - SamplingMethod: Non-Probability Sample
Changes in Intra-articular Parameters by Doppler Ultrasound in Patients With Hemophilic Ankle Arthropathy
Status: Not yet recruiting

Introduction: Hemophilic ankle arthropathy is manifested by functional degenerative alterations, intra-articular alterations, and chronic pain. Manual therapy techniques are used in the treatment of hemophilic ankle arthropathy for the improvement of pain and mobility.

Design. Double-blind randomized pilot trial. Aimed: To evaluate the ultrasound changes by means of Doppler imaging after manual therapy intervention.

Patients: A total of 20 adult patients with hemophilic ankle arthropathy will be recruited.

Intervention: Each manual therapy session will last approximately 50 minutes, with 1 session per week for a period of 3 weeks. The treatment program includes 10 techniques that will be administered bilaterally.

Measuring instruments: Patients will be evaluated qualitatively with ultrasound (HEAD-US scale) and assessment with Doppler ultrasound. The clinical variables will be joint damage (Hemophilia Joint Health Score) and pain intensity (Visual Analogue Scale).

Expected results: Check the safety of manual therapy in patients with hemophilia regarding subclinical bleeding. Assess changes related to joint inflammatory state with imaging techniques. Observe changes in pain intensity and joint damage.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients diagnosed with hemophilia A or B. Persons over 18 years of age. Patients with a medical diagnosis of ankle arthropathy (with clinical assessment of more than 4 points on the Hemophilia Joint Health Score. Patients on prophylactic or on-demand treatment with FVIII / FIX concentrates. Sign the informed consent document.  Exclusion Criteria:  Patients with inhibitors (antibodies against FVIII or FIX) without treatment with monoclonal antibodies. Patients with neurological or cognitive alterations that impede the comprehension of questionnaires and physical tests. Patients who have developed an ankle hemarthrosis in the 3 months prior to the study. Patients who at the time of the study are receiving ankle physiotherapy treatment. - HealthyVolunteers: No - Gender: Male - MinimumAge: 30 Years - MaximumAge: 55 Years - StdAgeList: Adult
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
Status: Recruiting

To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 6-18 years old (including both ends), male and female; Diagnosed with primary immune thrombocytopenia (ITP); Patients who had previously received eltrombopag treatment and then converted to avatrombopag treatment because of ineffectiveness (platelet count < 30×10^9/L after eltrombopag treatment, or platelet count increased less than 2 times of the basic value, or bleeding) or large platelet fluctuation or due to patient preference, economic reasons and other reasons; Cardiac function of the New York Society of Cardiac Function ≤ 2; Understand the study procedure and voluntarily sign the informed consent.  Exclusion Criteria:  Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.; Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases; Subjects who are known to be allergic to avatrombopag or any of its excipients; Subjects who had used rituximab within the last 3 months; Subjects who underwent splenectomy within the last 3 months； Subjects with a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements； Any medical history or condition that the investigator deems unsuitable for participation in the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 6 Years - MaximumAge: 18 Years - StdAgeList: Child, Adult
Improving Patient Understanding of Macrosomia
Status: Recruiting

The purpose of this study is to evaluate the effectiveness of a graphic based education tool on patient knowledge of macrosomia through the use of a survey and to evaluate knowledge at 1-2 weeks after initial review of the education tool.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  singleton pregnancy greater than or equal to 36 weeks gestation.  Exclusion Criteria:  unable to provide informed consent - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - MaximumAge: 55 Years - StdAgeList: Adult
A Study of the Association Between Frailty and Acute Postoperative Pain in Elderly Thoracoscopic Surgery Patients
Status: Not yet recruiting

To gain a clearer understanding of the association between frailty and postoperative acute pain in elderly thoracoscopic surgery patients and its underlying mechanisms, to provide new solution ideas to reduce the level of postoperative acute pain and improve the debilitating state of elderly thoracoscopic surgery patients, and consequently improve their quality of life and mental status.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  patients undergoing thoracic surgery under general anesthesia with 48 h of postoperative patient-controlled analgesia; age ≥60 years; ASA class I-III; signed informed consent; patients undergoing thoracoscopic surgery.  Exclusion Criteria:  Patients who themselves refuse to participate in the study; Drug dependence; Patients who cannot cooperate with communication and have verbal communication difficulties; Patients who cannot assess frailty preoperatively and pain postoperatively; Failure to provide a compliant fecal sample at the agreed time; antibiotic treatment within the last month; intestinal dysfunction (e.g., irritable bowel syndrome, inflammatory bowel disease, chronic diarrhea, and other types of intestinal disorders); comorbidities of certain metabolic disorders (e.g., thyroid dysfunction, diabetes mellitus, and so on) that may affect the structure of the microbial community; - HealthyVolunteers: No - Gender: All - MinimumAge: 60 Years - StdAgeList: Adult, Older Adult - StudyPopulation: It is proposed to observe cases with age greater than or equal to 60 years undergoing thoracoscopic surgery at Tongji Hospital from February 2024 to October 2024 who meet the inclusion and exclusion criteria. - SamplingMethod: Non-Probability Sample